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Abstract
Type I interferons (IFNa and b) are induced directly in response to viral infection, resulting in an antiviral state for the cell. In
vitro studies have shown that IFNa is a potent inhibitor of viral replication; however, its role in HIV-1 infection is
incompletely understood. In this study we describe the ability of IFNa to restrict HIV-1 infection in primary human
macrophages in contrast to peripheral blood mononuclear cells and monocyte-derived dendritic cells. Inhibition to HIV-1
replication in cells pretreated with IFNa occurred at an early stage in the virus life cycle. Late viral events such as budding
and subsequent rounds of infection were not affected by IFNa treatment. Analysis of early and late HIV-1 reverse transcripts
and integrated proviral DNA confirmed an early post entry role for IFNa. First strand cDNA synthesis was slightly reduced
but late and integrated products were severely depleted, suggesting that initiation or the nucleic acid intermediates of
reverse transcription are targeted. The depletion of integrated provirus is disproportionally greater than that of viral cDNA
synthesis suggesting the possibility of a least an additional later target. A role for either cellular protein APOBEC3G or
tetherin in this IFNa mediated restriction has been excluded. Vpu, previously shown by others to rescue a viral budding
restriction by tetherin, could not overcome this IFNa induced effect. Determining both the viral determinants and cellular
proteins involved may lead to novel therapeutic approaches. Our results add to the understanding of HIV-1 restriction by
IFNa.
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Introduction
Type I interferon (IFN) a and b can be induced directly in
response to viral infection and trigger the transcription of a diverse
range of IFN-stimulated genes (ISGs) through activation of the
Jak-STAT (signal transducer and activator transcription) pathway
[1]. This establishes an antiviral state in target cells. However,
most viruses can still replicate and cause disease in vivo, having
evolved strategies to at least partially avoid or inhibit the IFN
response. The efficiency by which the virus manages to circumvent
the antiviral actions of IFN is important in the establishment of a
productive infection.
Multiple clinical trials have tested the ability of IFNa to restrict
HIV-1 replication or slow disease progression [2,3,4,5,6]. Overall,
compared with the efficacy seen in treatment of viral infections
such as Hepatitis C, the in vivo effects of IFNa in HIV-1 infected
patients were modest at best, with conflicting results for negative
outcomes such as toxicity, antiretroviral treatment failure and
progression of HIV-1 disease. This was somewhat surprising as in
vitro studies in both cell lines and primary human cells showed that
IFNa is a potent inhibitor of HIV-1 infection, particularly in the
early stages [7,8,9,10,11,12,13,14]. The role of IFNa in HIV-1
infection is incompletely understood, however results from this and
other studies suggest that IFNa may regulate the expression of a
restriction factor/s able to specifically inhibit the replication of
HIV-1.
More recent work has linked the ability of IFNa to inhibit HIV-
1 infection in cell lines with a cellular membrane protein CD317
(tetherin) and known HIV-1 restriction factor APOBEC3G
[15,16,17]. Tetherin is upregulated by IFNa and inhibits the
release of newly assembled virions in cell lines. IFNa also
upregulates the level of APOBEC3G in primary human
macrophages. The enzymatic activity of APOBEC3G leads to
the degradation of HIV-1 DNA [18,19]. To mediate this effect
however, APOBEC3G must be incorporated into the virion and
thus is only able to restrict the establishment of new rounds of
infection. Incorporation of APOBEC into virions is prevented by
the viral accessory protein, Vif.
Here, we confirm previous studies in MDM and extend them to
describe a dramatic reduction in HIV-1 infection by IFNa in
primary human macrophages but interestingly not dendritic or T
cells derived from the same donors. Our experiments support data
indicating that IFNa acts at an early stage in the virus life cycle,
upon establishment of infection. Our analysis of integrated
proviral levels suggests the possibility of an additional target
between the completion of reverse transcription (RT) and
integration. The inhibition of replication is not due to IFNa-
induced action of tetherin or APOBEC3G. Rather we suggest
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IFNa inhibits HIV-1 through an as yet unknown cellular pathway,
possibly targeting the viral gag/pol, the reverse transcription
process itself or RT intermediates. Identification of the viral and
cellular factors involved in this response may provide novel
therapeutic approaches without the historical negative outcomes of
IFNa.
Results
IFNa dramatically inhibits HIV-1 replication in MDM but
not PBMC/MDDC
MDM, PBMC and MDDC were infected with HIV-1 89.6 in
the presence or absence of IFNa. Viral replication was determined
after 4–7 days following analysis of reverse transcriptase levels in
the culture supernatants. IFNa was shown to inhibit HIV-1
replication in MDM. In contrast pretreatment of PBMC and
MDDC with IFNa did not show any effect on the production of
new virions (Fig. 1a). This suggests that IFNa can mediate a
restriction to HIV-1 replication in a cell specific manner.
The general antiviral roles of the type I IFNs are well described,
and to determine the relative ability of members of this IFN family
to inhibit HIV-1, MDM were challenged with replication
competent HIV-1 strains BaL and 89.6 in the presence or absence
of IFNa or IFNb. The level of HIV-1 infection was determined
after 4 days by in situ intracellular p24 staining and enumeration of
FFU/ml. Fold reduction is the ratio of FFU/ml of no IFN
compared to IFNa treated cells. Replication in MDM by these
HIV-1 isolates is dramatically inhibited (up to 1000-fold) when
these cells are pretreated with IFNa (Fig. 1b). While it is known
that IFNb performs a unique role in viral infection and is essential
for a fully effective general antiviral response, the potency of HIV-
1 restriction was much less when MDM were pretreated with
IFNb. These data are consistent with previous reports that HIV-1
is susceptible to IFNa mediated inhibition [9,10]. Results for IFNb
have not been previously reported. In this study we specifically
investigate IFNa, and its ability to mediate restriction of HIV-1
infection.
Further analysis was then performed on an extended panel of
full length HIV-1 isolates. The well characterised macrophage-
(BaL, YU-2) and dual-tropic (89.6) HIV-1 strains along with
several primary isolates were used. HIV-1 isolates were dramat-
ically inhibited (up to 1000-fold) when these cells were pretreated
with IFNa (Fig. 1c). The extent of inhibition across the panel of
viruses tested was variable (10-1000-fold), indicating that some
Figure 1. IFNa potently inhibits HIV-1 replication in MDM but not PBMC/MDDC. (a) MDM, PBMC and MDDC were treated with 500 IU/ml
IFNa 24 hr prior to challenge with HIV-1 89.6. Culture supernatants were assayed after 4 days for levels of RT by ELISA (pg/ml). (b & c) MDM were
treated with 500 IU/ml IFNa or b 24 hr prior to infection with a panel of replication competent HIV-1. Infected foci were counted after 4 days. Fold
reduction is the ratio of FFU/ml of no IFN compared to IFNa treated cells. Error bars represent SD of one representative experiment.
doi:10.1371/journal.pone.0013521.g001
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isolates are less sensitive to the antiviral action of IFNa and
suggesting the evolution of viral escape mechanisms.
IFNa inhibits the establishment of infection and acts via
unknown cellular factor/s
MDM cultures were treated with IFNa at various times prior to,
at and post infection with HIV-1 strains 89.6 and BaL, previously
shown to be highly sensitive to its inhibitory effects. The most
potent restriction was observed when IFNa was present before the
cells were infected (Fig. 2a). IFNa was still seen to have a modest
effect on replication when added at the same time as the virus, but
this soon decreased to low/negligible levels if IFNa was introduced
after first round infection was complete (+24 hr). These results
show that suitable expression levels of antiviral proteins or non-
translated RNA can take at least 4 hr following induction by IFNa
(up to 24 hr for maximum effect) and suggest that the resultant
antiviral state is most effective at inhibiting the initial establish-
ment of infection.
APOBEC3G is a well known IFNa responsive gene that inhibits
HIV-1 replication at an early post entry stage (reviewed in [20]).
The action of APOBEC3G on nascent DNA requires its presence
in virions made by the producer cell. HIV-1 Vif counteracts the
action of APOBEC3G by preventing its incorporation into virions.
Here it is unlikely that APOBEC3G restriction is responsible for
the IFNa mediated inhibition because the HEK 293T producer
cells are APOBEC3G- [21]. Furthermore virion incorporation of
APOBEC3G is unlikely because all viruses are Vif+. It could be
argued however that the higher cellular levels of APOBEC3G
following IFNa induction overcome Vif mediated exclusion. This
could result in APOBEC3G being packaged into virions after first
round infection and contributing to the total inhibition. To
exclude this possibility, experiments were performed in which the
RT inhibitor AZT was introduced 24 hr post infection, to block
late stages and second round infection (Fig. 2b).
If late events or APOBEC3G contributed to the inhibition
induced by IFNa, we would expect a relative reduction of IFNa
mediated inhibition in cells treated with AZT. In MDM infected
with HIV-1 BaL and 89.6, no difference in the ability of IFNa to
restrict infection was observed in the presence or absence of AZT
(Fig. 2b), confirming the notion that IFNa-induced restrictions act
at an early stage of viral replication.
Figure 2. IFNa inhibits the establishment of infection and acts via unknown cellular protein/s. MDM were treated with 500 IU/ml IFNa
24 hr prior to infection with replication competent HIV-1 89.6 and BaL. Infected foci were counted after 4 days. (a) IFNa was added at various time
points prior to, at or after infection. (b) AZT (final concentration 100 nM) was added to cultures 24 hr post infection to block second round infection.
(c) HEK 293T cells were co-transfected with pcDNA3.1-HA-tetherin and either WT or Dvpu 89.6 molecular clones. Cells were lysed and the presence or
absence of tetherin was confirmed by Western blot using an anti-HA Ab. Tetherin is a 30–36 kDa protein that migrates as several species by SDS-
PAGE, as a result of post-translational modifications [15]. The levels of p24 protein were monitored as a loading control. (d) Supernatants from
transfected HEK 293T cells were serially diluted and used to infect NP2-CD4-CXCR4 cells. Virus titres were determined after 48 hr. (e) MDM were
challenged with tetherin resistant (WT) and tetherin sensitive (Dvpu) HIV-1 molecular clones 6 IFNa. Data is presented as mean 6 SD.
doi:10.1371/journal.pone.0013521.g002
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A role has recently been attributed to IFNa in the regulation of
tetherin (CD317, BST-2), a cell surface molecule capable of
inhibiting viral production. The inhibition is overcome by HIV-1
Vpu [15,16].
We determined whether the IFNa mediated restriction
described here could be due to the action of tetherin. We
engineered an HIV-1 molecular clone 89.6 with a premature stop
codon in vpu (89.6Dvpu). We first confirmed that the 89.6Dvpu
construct was susceptible to tetherin: HEK 293T cells were
cotransfected with HA-tagged tetherin and either wild type (WT)
or Dvpu HIV-1 89.6 molecular clones. Tetherin and viral protein
expression was confirmed by Western blot (Fig. 2c). The titre of
supernatants collected from these cultures was determined
confirming that tetherin was capable of inhibiting virus release
in these assays (Fig. 2d). The presence of tetherin had no effect on
WT 89.6 virus titre however, as expected, it was able to reduce the
titre of 89.6Dvpu at least 100-fold.
WT and Dvpu HIV-1 strains were then used to challenge MDM
in the presence or absence of IFNa. The results shown in Fig. 2e
demonstrate that Vpu is not required for the IFNa restriction, and
thus neither tetherin nor Vpu are involved in the IFNa induced
restriction in MDM. Supporting this, a reduction was also
observed in the levels of RT detected in the supernatants of
MDM, PBMC and MDDC cultures when challenged with
89.6Dvpu compared with WT 89.6 but no difference in the ability
of IFNa to restrict HIV-1 replication was observed (data not
shown). The IFNa mediated restriction described in this study
therefore, is distinct from the effects of tetherin and Vpu.
IFNa inhibits HIV-1 at an early post entry stage in the
virus life cycle
To probe the mechanism behind the inhibition of HIV in
MDM, we sought to determine the stage of the virus life cycle at
which IFNa was effective.
The lack of p24 protein in the MDM detected by staining for
FFU indicated that the IFNa mediated block of viral replication
was in the early part of the life cycle and at least prior to protein
translation. Furthermore to support this we isolated mRNA from
MDM infected with HIV-1 BaL and performed qRT-PCR to
determine whether the quantity of HIV-1 transcripts produced in
the presence of IFNa was affected. HIV-1 mRNA levels were
negligible in the presence of IFNa (Fig. 3a). These results support
the observations in Fig. 1c that IFNa acts at an earlier stage in the
viral life cycle.
To expand on these results and characterise the viral
determinants of IFNa restriction, MDM were infected with
HIV-1 pseudotypes carrying various retroviral and other enve-
lopes. Significant restriction was seen in all cases, most notably for
HIV-1 cores pseudotyped with VSV-G, for which 4-5-log
reductions in replication were observed (Fig. 3b).
Viruses pseudotyped with retroviral envelopes from feline
endogenous virus (RD114) and amphotrophic murine leukaemia
virus (Ampho) enter the cell following binding to the receptors
RDR and PiT2 respectively, while VSV-G triggers entry by
clathrin-mediated endocytosis through a ubiquitously expressed
glycolipid. Therefore these results show that IFNa mediated
restriction of HIV-1 is not dependent on the Env-host cell
interaction. IFNa may mediate a restriction that targets the viral
gag-pol.
Post entry restriction affects the kinetics of late HIV-1 RT
products in MDM but not PBMC/MDDC
To identify more precisely the post entry point of the restriction
induced by IFNa, qPCR analysis was performed on DNA
extracted from HIV-1 89.6 infected MDM at various time points
post infection. Early (negative strand strong stop, -sss), late (gag-
LTR) and integrated (Alu-gag) HIV-1 products were quantified.
The results in Fig. 4a confirm that inhibition occurs post entry, as
HIV-1 DNA products are detected in the presence and absence of
IFNa. No HIV-1 DNA products are detected in the presence of a
CCR5 inhibitor (data not shown). Up to 6 hr after virus challenge
the levels of both early and late HIV-1 DNA RT products are the
same in the presence or absence of IFNa, indicating the same
efficiency of viral entry. After 6 hr IFNa treated samples showed a
Figure 3. IFNa inhibits HIV-1 at an early post entry stage in the virus life cycle. (a) MDM were treated with 500 IU/ml IFNa 24 hr prior to
challenge with HIV-1 BaL. Cells were collected 0 and 24 hr post infection and total RNA was extracted. RT-qPCR was used to detect late HIV-1
products and results were normalised to GAPDH cDNA and compared with uninfected controls. Error bars represent SD of two independent
experiments. (b) HIV-1 89.6Denv was pseudotyped with VSV-G, RD114 and Ampho MLV envs and used to challenge MDM. Infected foci were counted
after 4 days and are presented as mean 6 SD.
doi:10.1371/journal.pone.0013521.g003
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delay in both RT products. This was more pronounced for late
RT transcripts, and more so for integrated proviruses, of which a
100-fold decrease was observed following treatment with IFNa.
Thus this IFNa-induced restriction acts after the initiation of RT,
preventing the completion and/or integration of full length
products.
We next compared the effect of IFNa on RT in PBMC and
MDDC. As expected from the infectivity data in Fig. 1a the
potency of any IFNa induced restriction(s) was much weaker in
PBMC and MDDC compared to MDM following analysis of the
kinetics of HIV-1 DNA production (Fig. 4b).
Discussion
Here we show a potent (3-log) IFNa induced antiviral response
against HIV-1 infection which is specific to MDM. The inhibition
of replication occurs after the virus delivers its capsid into the
cytoplasm, acting after initiation, but before completion of RT.
We have excluded the involvement of previously described IFNa
responsive genes tetherin or APOBEC3G.
The overall modest responses of HIV-1 infected patients to IFN
therapy in past years [2,3,4,5,6] have forced researchers to
investigate alternative strategies for the development of pharma-
Figure 4. Post entry restriction affects the kinetics of late HIV-1 RT products and integration in MDM but not PBMC/MDDC. (a) MDM
and (b) PBMC and MDDC were treated with 500 IU/ml IFNa 24 hr prior to challenge with HIV-1 BaL. Cells were collected at various time points after
infection and DNA was extracted. Early (MDM), late (MDM, PBMC & MDDC) and integrated (MDM) HIV-1 DNA was normalised to genomic GAPDH and
copy number is presented per 106 cells. Data is presented as mean 6 SD and is from one representative experiment.
doi:10.1371/journal.pone.0013521.g004
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ceuticals to control disease progression. Subsequently, while long
observed, the inhibitory effects of IFNa on HIV-1 replication in
primary cells are relatively poorly understood. Here we have taken
further steps in identifying and characterising its specific action on
HIV-1 infection of primary human macrophages.
It has previously been reported that IFNa preferentially inhibits
HIV-1 replication in MDM compared with CD4+ T cells [10].
Here we confirm this observation using RT ELISA and real-time
qPCR analysis (Fig. 1a and 4b). We build upon previous studies of
this nature with analysis of MDDC, in which we show a profile of
HIV-1 replication more similar to PBMC than MDM. Thus we
confirm the strong antiviral response to IFNa to be cell type
specific, which may contribute to the more refractory nature of
macrophages to HIV-1 infection than T-cells in vivo.
qPCR analysis of DNA from various time points following HIV-
1 infection of MDMs shows that, on top of an overall decrease in
the total amount of detectable reverse transcribed HIV-1 DNA,
IFNa acts at a point after the initiation of reverse transcription
which specifically delays the completion of full-length preintegra-
tion genomes and significantly reduces the levels of integrated
provirus. This is supported by our observation of the redundancy
of HIV-1 Env in determining susceptibility to IFNa, which
indicates that this effect is not dependent on the Env-host cell
interaction. The restriction acts after the viral core is uncoated and
released into the cytoplasm, suggesting that the HIV-1 gag/pol, the
reverse transcription process and events leading to integration may
be targeted.
Analysis of the levels of integrated viral DNA following
treatment with IFNa shows a 100-fold decrease compared with
untreated samples 24 hr post infection. Yet there is only a 10-fold
decrease in late RT products which could point to the existence of
additional blocks after reverse transcription but before completion
of integration due to the upregulation and action of multiple ISGs.
As the experiments in this study were performed using
replication competent viruses, it was important to determine the
extent to which the overall inhibition described could be
accounted for by the action of known HIV-1 specific IFNa-
inducible proteins tetherin and APOBEC3G. We have excluded a
role for either protein in this IFNa mediated antiviral effect.
Tetherin was excluded following the comparison of WT (tetherin
resistant) and Dvpu (tetherin sensitive) HIV-1 viruses wherein no
difference in the ability of IFNa to restrict was observed.
Interestingly, in a recent report of potential IFNa-induced
antiviral genes, tetherin was upregulated less than 2-fold in
MDM [22].
Evidence for IFNa regulation of APOBEC3G as an important
intracellular defence against HIV-1 infection is compelling. It is
unlikely that the IFNa mediated restriction described in this study
is due to APOBEC3G. All viruses were Vif+ and produced in the
absence of APOBEC3G. However it could be argued that IFNa
overcomes APOBEC3G sequestration by HIV-1 Vif, allowing
enhanced APOBEC3G packaging into budding virions. Our data
using AZT to inhibit subsequent rounds of infection demonstrates
that this scenario is unlikely as there was no relative difference in
the potency of IFNa mediated restriction in the presence of AZT.
Generally, the IFNs are known to have wide ranging protective
immunomodulatory, antiproliferative and antiviral effects, and
exert their activity through multiple pathways. Effector proteins
and pathways induced by IFN include protein kinase regulated by
RNA (PKR)/eukaryotic initiation factor 2a (eIF-2a) for mRNA
translation inhibition, RNase L for RNA degradation, adenosine
deaminase acting on RNA (ADAR1) for RNA editing and others
such as protein GTPase Mx and nitric oxide synthetase (NOS)
(reviewed in [23]). In the case of HIV-1 infection, IFNa can itself
be regulated by cytokines such as IL-27 [24], and has been
implicated in the antiviral actions of activator proteins such as
tetherin [15] and APOBEC3G [17,25]. In addition to these
mechanisms, we describe a role for IFNa in the early stages of
establishment of initial infection that is peculiar to primary MDM.
In the last few years, several groups have characterised the
ability of the retroviral protein Vpx to rescue HIV-1 infection in
MDM by overcoming a restriction imposed by an unknown
antiviral factor in these cells [26,27,28]. More recently, one study
has suggested that the cellular factor overcome by Vpx is IFNa-
inducible, as introduction of Vpx into IFNa treated MDM prior to
HIV-1 infection rescues the level of inhibition approximately 100-
fold [29]. The phenotype of the Vpx-counteractable restriction
bears many similarities to the IFNa mediated restriction described
here, as the antiviral action is at an early stage in the viral life cycle
and the accumulation of full length reverse transcripts is
prevented.
It seems unlikely that the cellular restriction factors responsible
for the Vpx-counteractable phenomenon and the inhibition
described here are one and the same. A recent study demonstrates
that primate and nonprimate lentiviruses containing Vpx are also
susceptible to restriction by IFNa [14]. Together with the
observation that Vpx is not able to completely rescue HIV-1
from IFNa mediated inhibition, and that it has been shown to
have the same enhancement of viral infection in MDDC [30] does
not completely explain the total impact of IFNa on HIV-1
replication and thus it is likely that other unidentified IFNa-
inducible antiviral factors exist.
Macrophages have a key role in the success of the innate
immune response. A recent paper shows that HIV-1 infected
MDM fail to produce type I IFNa suggesting that HIV-1 can
specifically interfere with the IFNa mediated response to establish
infection in vivo [31]. If the cellular proteins involved in this
interference can be determined and targeted, without the toxicities
and negative disease outcomes of previous IFNa therapies, further
rounds of macrophage infection may be eliminated. Additionally,
cell-cell transmission and/or establishment of cellular reservoirs
with the potential to generate drug resistant strains may be
reduced, enhancing the effectiveness of current long-term ART
regimens [32].
Materials and Methods
Cells
Buffy coats from seronegative donors were obtained from the
National Blood Service (Brentwood, UK). Donors were anony-
mous and thus patient consent was not required. Peripheral blood
mononuclear cells (PBMC) were prepared by density-gradient
centrifugation (Lymphoprep, Axis-Shield). Monocyte-derived
macrophages (MDM) were prepared by adherence as described
previously [33]. Cells were plated at 26106 cells/ml and left to
differentiate for 7–14 days in RPMI 1640/20% autologous human
serum and 20 ng/ml macrophage colony stimulating factor (M-
CSF; R&D Systems).
PBMC were cultured from the same donor at 26106 cells/ml in
RPMI 1640, supplemented with 10% foetal calf serum (FCS;
Biosera), 1% penicillin/streptomycin (PAA) and phytohemagglu-
tinin (PHA-P, 0.5 mg/ml; Sigma). After 3–5 days, PHA-P was
replaced by recombinant human interleukin-2 (rhIL-2, 20 U/ml;
Invitrogen).
Monocyte-derived dendritic cells (MDDC) were isolated from
PBMC using CD14+ MACS Microbeads (Miltenyi Biotech) and
were cultured for 7 days in RPMI 1640/10% FCS, 1% penicillin/
streptomycin, recombinant human interleukin-4 (rhIL-4, 50 U/
IFN-Alpha Restriction of HIV-1
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ml; R&D Systems) and recombinant human granulocyte-macro-
phage colony stimulating factor (GM-CSF, 0.1 mg/ml; Sigma).
HEK 293T [34] cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM; Invitrogen) with 10% FCS and 1%
penicillin/streptomycin. DMEM for NP2-CD4-CXCR4 [35] cells
additionally contained geneticin (G418, 1 mg/ml; Melford
Laboratories) and puromycin (1 mg/ml; PAA).
Plasmid constructs
HIV-1 89.6Dvpu and 89.6Denv were generated from the 89.6
molecular clone using overlap extension PCR. For 89.6Dvpu, the
fragments obtained with the primers 89.6-ERI-F/Vpu stop-XbaI-
R (89.6-ERI-F 59-GGAGTGGAAGCCTTAATAAGAATTCT-
GCA-39, Vpu stop-XbaI-R 59-GCTAATATTTGTCTAGAA-
AGTTATACATGTAC-39) and Vpu stop-XbaI-F/89.6-StuI-R
(Vpu stop XbaI-F 59-GTACATGTATAACTTTCTAGACAAA-
TATTAGC-39, 89.6-StuI-R 59- GATACCTTTGGACAGGC-
CTGTGTA-39) were used as a template for another PCR using
the primers 89.6-ERI-F/89.6-StuI-R. The resulting fragment was
cloned at EcoRI and StuI sites in the 89.6 molecular clone. For
89.6Denv, the fragments obtained with the primers 89.6-ERI-F/
Env stop-HIII-R (Env stop-HIII-R 59-TCCTGATCTCCTT-
CAAGCTTTATGCCACTGTC-39) and Env stop-HIII-F/89.6-
StuI-R (Env stop HIII-F 59-GACAGTGGCATAAAGCTT-
GAAGGAGATCAGGA-39) were used as a template for another
PCR using the primers 89.6-ERI-F/89.6-StuI-R. The resulting
fragment was cloned at EcoRI and StuI sites in the 89.6 molecular
clone.
To generate the HA-tagged pcDNA3.1-tetherin construct,
tetherin coding sequence was amplified using forward (59-C-
ACACACACACAGCGGCCGCATGTACCCATACGATGT-
TCCAGATTACGCTATGGCATCTACTTCGTATGACTA-
39) and reverse (59-CACACACACACAGGATCCTCACTGC-
AGCAGAGCGCTGA-39) primers from 293T cDNA and cloned
in-frame at NotI and BamHI sites in the pcDNA3.1(-) expression
vector (Invitrogen).
Primary HIV-1 stocks
2005 and HAN-2 were isolated as previously described [36]. All
primary strains were minimally passaged in PBMC to expand
virus stocks.
Virus stocks
Virus stocks were prepared from infectious full-length and
chimeric HIV-1 clones by polyethylenimine (PEI; Polysciences)
transfection of HEK 293T cells. Infectivity assays. NP2-CD4-
CXCR4 cells were seeded in 48-well trays at 1.56104 cells/well in
200 ml antibiotic-free DMEM. The following day viruses were
added to the cells and incubated for 2 hr before the media was
changed. Cells were cultured for 48 hr before infection was
assessed following intracellular p24 staining.
MDM in 48-well trays (46105 cells/well) were infected with
500–5000 FFU viral stock (titred on NP2 cells) in 200 ml RPMI
1640/20% autologous serum. Media was replaced after 24 hr and
virus production was detected after 4 days following intracellular
p24 staining.
Time courses of virus infectivity of MDM, PBMC and MDDC
were performed in 12- and 24-well trays. Cells were infected 3–5
days (PBMC) or 7 days (MDM and MDDC) post isolation.
500 IU/ml IFNa was added 24 hr prior to infection where
appropriate. CCR5 coreceptor inhibitor SCH-D (10 nM) was
added 1 hr before infection. MDM were challenged with 6000
focus forming units (FFU) virus/well in a total of 1 ml RPMI
1640/20% autologous serum while all PBMC or MDDC were
initially pooled, pelleted and challenged with 250000 FFU virus.
2 hrs after infection these cells were divided into 24-well plates and
made up to 1 ml in RPMI 1640/10% FCS supplemented with
appropriate cytokines. At the collection of each time point, cells
were washed twice with PBS.
Determination of RT activity
Virus supernatants from infections were assessed for RT activity
by RT-ELISA (Cavidi Tech Inc.).
In situ immunostaining for p24 antigen
Infected cells were fixed with cold (220uC) methanol:acetone
(1:1), washed with PBS then immunostained for p24 using mouse
anti-HIV-1 p24 monoclonal antibodies EVA365 and 366 (NIBSC,
UK) (diluted 1:50), as previously described [37]. Infected cells were
blue (regarded as foci of infection (FFU/ml)) and counted by light
microscopy.
Western blot
Western blots carrying lysed HEK 293T extracts were first
incubated with primary antibody (rat anti-HA or human anti-p24)
followed by the appropriate HRP-conjugated antibodies. Proteins
were visualised using a chemiluminescence kit (ECL, Amersham
Biosciences).
First round Alu-gag PCR
DNA was extracted at various time points after infection with a
QIAamp DNA Blood Mini Kit (QIAGEN). Integrated HIV-1
DNA was measured using a nested PCR protocol, as previously
described [38]. Briefly, a standard curve was prepared using a
1:1:1 ratio of genomic DNA from chronically HIV-1 infected cell
lines ACH-2 [39], 8E5/LAV [40] and OM-10.1 [41] in a
background of HeLa genomic DNA (data not shown). First round
products were amplified using 300 nM each primer (Alu-F 59-
GCCTCCCAAAGTGCTGGGATTACAG-39; gag-R 59-GTT-
CCTGCTATGTCACTTCC-39) and approximately 50 ng total
DNA in a 25 ml reaction. PCR conditions consisted of one cycle of
denaturation (94u for 2 min), 39 cycles of amplification (94u for
15 sec, 50u for 30 sec, 68u for 8 min), and one cycle of 68u for
7 min. 5 ml of resulting PCR product was used as the template for
measurement of integrated HIV-1 DNA in a nested real-time
quantitative PCR.
Real-time quantitative PCR for HIV-1 DNA
The isolated DNA was subjected to real-time quantitative PCR
(qPCR) to determine the number of early (negative strand strong
stop, -sss) and late (gag) transcripts present, normalised for cell
number by genomic GAPDH. Integrated HIV-1 DNA copies
were determined in a nested qPCR using 5 ml of first round
product as template. Each 25 ml reaction contained the following
components: 16 MegaMix-Gold PCR buffer (Microzone),
300 nM each forward primer (early 59-GCTAACTAGGGAACC-
CACTGCTT-39; late 59-tgggcaagcagggagcta-39; genomic GA-
PDH 59-GAAGGTGAAGGTCGGAGT-39; integrated 59- T-
TAAGCCTCAATAAAGCTTGCC-39), 300 nM each reverse
primer (early 59-CAACAGACGGGCACACACTACT-39; late
59-tcctgtctgaagggatggttgt-39; genomic GAPDH 59-CATGGGTG-
GAATCATATTGGAA-39; integrated 59- GTTCGGGCGC-
CACTGCTAGA-39), 150 nM each probe (early 59-CY3-AG-
CCTCAATAAAGCTTGCCTTGAGTGCTTC-BHQ2-39; late
59-6-FAM-aacgattcgcagttaatcctggcctgtt-BHQ1-39; genomic GAP-
DH 59-CY5-CAACGGATTTGGTCGTATTGGGCGC-BHQ2-
39; integrated 59- CY3-CCAGAGTCACACAACAGACGGG-
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CACA-BHQ2-39) and approximately 500 ng total DNA (early,
late, GAPDH) or 5 ml of first round Alu-gag PCR product
(integrated). A standard curve was prepared with the NL4.3
molecular clone (early and late HIV-1 DNA) and HEK 293T
genomic DNA (GAPDH) in a background of 200 ng salmon
sperm carrier DNA (data not shown). PCR conditions consisted of
one cycle of denaturation (95uC for 5 min) followed by 40 cycles of
amplification (95uC for 15 sec, 60uC for 1 min). Data acquisition
and analysis was performed using the ABI PRISM 7500 SDS
software.
cDNA synthesis
Total RNA was extracted from MDM using an RNeasy Plant
Mini Kit (QIAGEN) and cDNA was synthesised with Superscript
III First Strand Synthesis System (Invitrogen), according to
manufacturer’s instructions. The cDNA produced was subjected
to real-time qPCR as above, using the primer/probe set
designated ‘late’, and was normalised for input cDNA by primers
and probe targeting GAPDH transcripts (300 nM forward primer
GAPDH 59- CCACATCGCTCAGACACCAT-39,300 nM re-
verse primer GAPDH 59-CCAGGCGCCCAATACG-39, 150 nM
probe GAPDH 59-6-FAM-AGGTGAAGGTCGGAGTCAACG-
GATTTG-BHQ1-39).
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